Preclinical
The following is a roundup of presentations and findings from multiple companies participating in the 2018 American Association for Cancer Research (AACR) in Chicago.
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.
Kineta Chronic Pain signed an exclusive option and license deal with Genentech. The two companies will develop Kineta’s alpha9/alpha10 nicotinic acetylcholine receptor (nAChR) antagonists to treat chronic pain.
Constellation Pharmaceuticals closed on a financing round worth $100 million. The company plans to use the funds to advance several clinical trials.
A company focused on aging-related ailments is looking to infuse new life into its coffers through an initial public offering. Unity Biotechnology is seeking to raise $85 million in the IPO as it takes its lead candidate into the clinic later this year.
SignalRx Pharmaceuticals Inc., a clinical-stage company developing novel small-molecules therapeutics via in-silico design to simultaneously inhibit multiple key orthogonal and synergistic oncotargets for the treatment of cancer, today announced the presentation of its novel triple CDK4-6/PI3K/BRD4 inhibitor program and first-in-class triple inhibitor SRX3177.
Shares of Arsanis, Inc. are inching up this afternoon following the company’s announcement of a licensing deal with Austria-based BB100, LLC, a subsidiary of Bravos Biosciences.
Company shares spiked 12.4 percent higher in premarket trading today after the U.S. Food and Drug Administration (FDA) granted Proteostasis Therapeutics’ triple combination for cystic fibrosis (CF) Fast Track Designation.
The $40 billion market for nonalcoholic steatohepatitis (NASH) is becoming a little more crowded. Less than one year after launching Terns Pharmaceuticals acquired exclusive licensing rights to three small molecule therapeutic NASH candidates from Eli Lilly.
Arvinas closed a $55 million Series C financing round. The funds will be used to advance Arvinas’ two lead cancer programs into the clinic.
PRESS RELEASES